David P Luci bought $50k of ACXP
President and CEO at Acurx Pharmaceuticals, Inc.. 49,261 shares at an average of $1.02, traded Jan 6, 2025, filed Jan 8, 2025.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- 0Relative to holdingsHoldings up 4.7%
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.1%, 3m -56.2%, 6m -33.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-002052, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 6, 2025 | POpen-market purchase Common Stock | +49,261 | $1.02 | $50k | 1,097,458 | Jan 8, 2025 |
| Jan 6, 2025 | POpen-market purchase Warrants for Common Stockderivative | +49,261 | $0.00 | $0 | 49,261 | Jan 8, 2025 |
Related signals
Other insiders at Acurx Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Acurx Pharmaceuticals, Inc. | Jack H Dean director | $10,000 9,852 shares | +83% | |
| 40Moderate | Acurx Pharmaceuticals, Inc. | Robert J Deluccia director, owner | $50k 49,261 shares | +5% | |
| 40Moderate | Acurx Pharmaceuticals, Inc. | James J. Donohue director | $10,000 9,852 shares | +79% | |
| 41Moderate | Acurx Pharmaceuticals, Inc. | Carl Sailer director | $25k 24,631 shares | +22% | |
| 45Moderate | Acurx Pharmaceuticals, Inc. | Joseph C Scodari director | $25k 24,631 shares | +800% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.